Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise

Not Applicable

Recruiting

• Conditions: Obesity
• Interventions: Procedure: Muscle Biopsy; Procedure: Adipose Biopsy; Other: Glucose Clamp; Other: Accelerometer; Other: Physical activity/ dietary habits; Other: Endurance Exercise; Other: Heavy Water Labeling Period

• Registration Number: NCT06602141
• Lead Sponsor: AdventHealth Translational Research Institute

Brief Summary

The purpose of this research study is to study the effects of endurance exercise training on adipose (fat) tissue quality and insulin sensitivity in men and women.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-08-19
• Study Start: 2024-09-11
• Study First Submitted QC: 2024-09-17
• Study First Posted: 2024-09-19
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-17
• Last Update Posted: 2025-03-19
• Primary Completion: 2029-04
• Study Completion: 2029-04

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

1. Men and pre-menopausal women;
2. 18-45 years of age;
3. BMI 30.0-40.0 kg/m2;
4. For women, if not using pharmaceutical (hormonal) contraception (i.e. birth control pills, vaginal ring, injections, or implant), must agree to use either a double barrier method as a form of birth control to prevent pregnancy (i.e. male condom with spermicide, with or without cervical cap or diaphragm); use implants or intrauterine contraceptive devices; have a tubal ligation (surgically sterile); practice abstinence; or be in an established relationship with a vasectomized or same sex partner during the entire duration of the study;
5. Able to speak and understand written and spoken English;
6. Sedentary defined as self-reporting no more than 1 day per week, lasting no more than 60 minutes, of regular (structured) endurance or resistance exercise in the past year.
7. Must be willing to be randomized to either study group;
8. Must be willing to adhere to all study procedures.
9. Participant has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.

Exclusion Criteria

1. Self-reported unstable body weight in the last 3 months (> ±5%);

2. Significant changes in the quality of the diet or the level of physical activity within the last 3 months;

3. Weight >396 lb (180 kg);

4. Diagnosis of Type 1 or Type 2 diabetes mellitus;

5. Fasting blood glucose ≥126 mg/dL;

6. HbA1c ≥ 6.5%

7. Blood pressure >140/90 mmHg ;

8. Self-reported history or presence of the following cardiovascular conditions: congestive heart failure, coronary artery disease, significant valvular disease, congenital heart disease, serious arrhythmia, stroke, symptomatic peripheral artery disease, stable angina, myocardial infarction or coronary revascularization within 6 months; clinically significant abnormalities on ECG, presence of cardiac pacemaker, or implanted cardiac defibrillator; inability to complete the VO2max test;

9. Anemia (hemoglobin <12 g/dl in men or 11 g/dl in women; Hct <34%);

10. Kidney disease (creatinine >1.6 mg/dl or estimated glomerular filtration rate <60 mL/min/1.73m2);

11. Abnormal liver enzymes (>2 times the upper limit of normal) that are clinically significant;

12. Serious digestive disorders including severe gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), Crohn's disease, chronic constipation and/or diarrhea, etc.;

13. Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy;

14. Current or history of eating disorders;

15. Abnormal bleeding or coagulopathy (self-report) or history of a bleeding disorder or clotting abnormality;

16. Clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD);

17. Dyslipidemia (fasting triglycerides >500 mg/dL; low-density lipoprotein cholesterol (LDL-C) >190 mg/dL);

18. Whole blood donation in the last 3 months or platelet/plasma donation in the last week or plans for donation during entire protocol period;

19. Receiving active treatment (including monoclonal antibodies) for autoimmune disorders within the last 6 months;

20. Alcohol consumption >7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month);

21. Current smokers (smoking or use of any tobacco or e-cigarette/e-nicotine/THC/cannabis products in the last 3 months); stopped smoking <10 years at time of screening for those with a >20 pack-year smoking history or stopped smoking <5 years at time of screening for those with a <20 pack-year smoking history;

22. Night shift work in the last 6 months or planning night shift work during the study period;

23. Known allergy to lidocaine or other local anesthetic;

24. Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting;

25. Previous bariatric or other surgery for obesity;

26. History of cancer (other than non-melanoma skin cancer) within the last 5 years (not in remission); anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months;

27. Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year;

28. Currently pregnant (pregnancy test performed on day of DEXA scan in women of child-bearing potential); post-partum during the last 12 months; lactating during the last 12 months; planning to become pregnant during the participation period;

29. Polycystic Ovarian Syndrome (PCOS) (self-report);

30. Metabolic bone disease (self-report) including history of non-traumatic fracture from a standing height or less and/or current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen;

31. Hospitalization for COVID-19 infection in the past 12 months; individuals who tested positive for COVID-19 but were not hospitalized must be symptom-free at least 14 days;

32. Partial and/or full hysterectomy (self-report);

33. Not willing to archive biospecimens for future use;

34. Not willing to undergo the microdialysis procedure;

35. Participants who fulfill any of the contraindications for MRI including metal implants, devices, paramagnetic objects contained within the body and excessive or metal-containing tattoos;

36. Unable to participate in MR assessments due to claustrophobia or physical limitations of equipment tolerances (e.g., MRI bore size) based on investigator's judgment at screening;

37. Positive toxicology result from screening;

38. The following medication use is exclusionary:

    • Dose change for any chronic-use drug in the last 3 months;
    • Cardiovascular: beta blockers and centrally acting anti-hypertensive drugs, anticoagulants, antiarrhythmics, and antiplatelet drugs (other than aspirin ≤100 mg/day);
    • Psychiatric: chronic use of medium- or long-acting sedatives and hypnotics, including all benzodiazepines (short-acting non-benzodiazepine sedative-hypnotics are allowed), mood stabilizers, antiepileptic drugs, stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs, anti-psychotic drugs;
    • Pulmonary/Inflammation: chronic oral steroids (inhaled steroids are allowed), burst/taper oral steroids more than once in the last 12 months, B2-agonists (allowed if on stable dose at least 3 months);
    • Genitourinary: 5-alpha reductase inhibitors, daily phosphodiesterase type 5 inhibitor;
    • Hormonal: androgenic anabolic steroids, anti-estrogens, anti-androgens, estrogens and/or progestins used for reasons other than birth control, growth hormone, insulin like growth factor-I, growth hormone releasing hormone, any drugs used to treat diabetes mellitus or lower blood glucose, metformin for any indication, any drugs used specifically to induce weight loss, any drugs used specifically to induce muscle growth/hypertrophy or augment exercise-induced muscle hypertrophy;
    • Pain/Inflammation: narcotics and narcotic receptor agonists, regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen, muscle relaxants ≥2 days per week;
    • Other: chronic systemic antimicrobials (antibiotic, antiviral, antifungal, antiparasite, etc.) for any reason, high-potency topical steroids if ≥10% surface area using rule of 9s, continuous/chronic use of antibiotics or other anti-infectives for treatment or prevention, monoclonal antibodies, anti-rejection medications/immune suppressants;

39. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control (CTRL) group	Muscle Biopsy	-
Control (CTRL) group	Adipose Biopsy	-
Control (CTRL) group	Glucose Clamp	-
Control (CTRL) group	Accelerometer	-
Control (CTRL) group	Physical activity/ dietary habits	-
Control (CTRL) group	Heavy Water Labeling Period	-
Endurance exercise (EX) group	Muscle Biopsy	-
Endurance exercise (EX) group	Adipose Biopsy	-
Endurance exercise (EX) group	Glucose Clamp	-
Endurance exercise (EX) group	Accelerometer	-
Endurance exercise (EX) group	Endurance Exercise	-
Endurance exercise (EX) group	Heavy Water Labeling Period	-

Primary Outcome Measures

Name	Time	Method
In vivo adipogenesis	Before and following 12 weeks of deuterium (2H) labelled water administration and either endurance exercise training or control (no exercise)	A subcutaneous white adipose tissue biopsy from the abdomen will be collected before and after 12 weeks of deuterium (2H) labelled water administration and either endurance exercise training or control (no exercise). New adipocyte formation will be assessed on frozen isolated 2H2O labelled adipose tissue cells

Trial Locations

Locations (2)

AdventHealth Translational Research Institute; 🇺🇸 Orlando, Florida, United States

Pennington Biomedical Research Center; 🇺🇸 Baton Rouge, Louisiana, United States